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index and  GLSsys yielded the best results on predicting 
death within 1 year (100% with Tei index ≥0.9 and  GLSsys 
≤13%) or survival (95% with Tei index ≤0.9 and  GLSsys 
≥13%). We conclude that 1-year mortality risk in AL-CA 
patients can be reliably predicted using Tei index or defor-
mation parameters, with combined analysis  offering best 
performance.
Keywords Tei index · Strain rate · Cardiomyopathy · 
Tissue Doppler echocardiography
Introduction
Primary amyloidosis formed from immunoglobulin light 
chain (AL) is one of the main types of systemic amyloi-
dosis, most commonly involving the kidneys and the heart 
[1]. Cardiac involvement (CA) is a leading cause of mor-
bidity and mortality in AL amyloidosis [2].
Echocardiography plays an important role in the diag-
nosis and disease progression monitoring of CA patients. 
Typical morphological findings of CA include left ven-
tricular (LV) hypertrophy, biatrial enlargement, and small 
pericardial effusion. Diastolic dysfunction usually occurs at 
the early stage, whereas LV ejection fraction remains nor-
mal until the late stage. Previous studies have reported the 
diagnostic and prognostic utility of conventional echocar-
diographic parameters and advanced deformation param-
eters in patients with AL-CA [3–5]. Results from our group 
and others demonstrated that longitudinal systolic and dias-
tolic deformation parameters derived from speckle track-
ing imaging (STI) could effectively predict the outcome of 
AL-CA patients [6–8].
As early as 1996, Tei and colleagues reported that the 
pulsed Doppler-derived Tei index, a simple parameter 
Abstract Prognosis of patients with light-chain cardiac 
amyloidosis (AL-CA) is poor. Speckle tracking imaging 
(STI) derived longitudinal deformation parameters and 
Doppler-derived left ventricular (LV) Tei index are valu-
able predictors of outcome in patients with AL-CA. We 
estimated the prognostic utility of Tei index and defor-
mation parameters in 58 comprehensively phenotyped 
patients with AL-CA after a median follow-up of 365 days 
(quartiles 121, 365 days). The primary end point was all-
cause mortality. 19 (33%) patients died during follow-up. 
Tei index (0.89 ± 0.29 vs. 0.61 ± 0.16, p < 0.001) and E to 
global early diastolic strain rate ratio (E/GLSRdias) were 
higher while global longitudinal systolic strain  (GLSsys) 
was lower in non-survivors than in survivors (all p < 0.05). 
Tei index, NYHA functional class,  GLSsys and E/GLSRdias 
were independent predictors of all-cause mortality risk, and 
Tei index ≥0.9 (HR 7.01, 95% CI 2.43–20.21, p < 0.001) 
was the best predictor of poor outcome. Combining Tei 
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reflecting both systolic and diastolic myocardial perfor-
mance, correlated with global cardiac dysfunction and 
was a valuable outcome predictor in CA patients [9, 10]. 
Tei index can be calculated by both pulsed Doppler and tis-
sue Doppler (TD) methods. The major limitation of the Tei 
index assessment using pulsed Doppler is that it cannot be 
measured within one cardiac cycle, while the TD method 
enables measurement of both relaxation and contraction 
velocities simultaneously [11].
In this study, we compared the prognostic utility between 
TD derived Tei index and STI derived deformation param-
eters as well as the incremental impact of these parameters 
in patients with AL-CA during 1-year of follow-up.
Methods
Study population and clinical follow-up
A total of 58 consecutive biopsy-proven AL-CA patients 
referred to the University Hospital Würzburg and Univer-
sity Hospital Center Zagreb between January 2005 and 
October 2014 were enrolled in this retrospective study. 
Cardiac involvement was diagnosed according to echocar-
diographic findings as described in our previous studies 
[6, 12]. Patients with coronary artery disease, higher grade 
cardiac valve diseases, and other cardiac pathologies were 
excluded. Written informed consent was obtained from 
all patients or their guardians. The study was approved by 
the local Ethics Committee at the University of Würzburg 
and University Hospital Center Zagreb, and conducted 
in accordance to the Declaration of Helsinki. All patients 
completed a 1-year follow-up performed by clinical visit or 
telephone interview. The primary end point was all-cause 
mortality.
Standard echocardiographic measurements
A standard echocardiographic examination was per-
formed in all patients (GE Vingmed Vivid 7 or Vivid 9, 
Horten, Norway). Measurements were performed off-line 
using a remote workstation (EchoPAC version 112, GE, 
Horten, Norway). LV end-diastolic dimension (LVEDD), 
end-diastolic thickness of the posterior wall (LVPWd) 
and the septum (IVSd), LV stroke volume, and fractional 
shortening (FS) were measured using M-mode in the 
parasternal LV long axis view. Left atrial end-systolic 
diameter was measured in the parasternal long-axis view. 
LV biplane Simpson method ejection fraction (EF) was 
measured in apical 4- and 2-chamber views. Septal mitral 
annular plane systolic excursion (MAPSE) was measured 
by M-mode in apical 4-chamber view. LV filling pattern 
was assessed according to current guidelines [13]. Pulsed 
Doppler was performed in the apical 4-chamber view to 
obtain mitral inflow velocities. Peak velocity of early (E) 
and atrial (A) diastolic filling and deceleration time of E 
wave (DT) were measured and the E/A ratio calculated. 
Tissue Doppler early diastolic mitral annular velocity (E′) 
was acquired at the septal mitral annulus.
Tissue Doppler derived Tei index measurement
Interval measurements were performed within one car-
diac cycle as illustrated in Fig.  1. The TD derived Tei 
index was calculated: (MCO-ET)/ET, where MCO is the 
time interval from the end of the TD late diastolic annular 
velocity A′ wave to the onset of the E′ wave, representing 
the mitral valve closure-to-opening time, and ET is the 
time from the onset to the end of the TD systolic annular 
velocity S′ wave, reflecting the ejection time of the LV. 
Isovolumetric contraction time (IVCT) was measured 
from the end of the A′ wave to the onset of the S′ wave, 
and isovolumetric relaxation time (IVRT) was measured 
from the end of the S′ wave to the onset of the E′ wave. 
The Tei index values from 3 (sinus rhythm) to 5 (atrial 
fibrillation) cardiac cycles were averaged.
STI-derived systolic and diastolic deformation
Standard 2D grey scale apical 4-chamber view was 
recorded and STI was analyzed off-line using EchoPAC 
post processing program version 112 (GE, Horten, 
Fig. 1  Example of a Tissue Doppler derived Tei index. Time inter-
vals of left ventricle are measured with tissue Doppler imaging and 
the Tei index is calculated by the formula: (MCO-ET)/ET. MCO 
mitral valve closure-to-opening time, ET ejection time, IVCT isovolu-
metric contraction time, IVRT isovolumetric relaxation time, S′ peak 
systolic septal mitral annular velocity, E′ peak early-diastolic septal 
mitral annular velocity, A′ peak late-diastolic septal mitral annular 
velocity
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Norway) as previously described [7]. Global longitudinal 
systolic peak strain rate  (GLSRsys) and strain  (GLSsys) at 
the midline, and global longitudinal peak early diastolic 
strain rate  (GLSRdias) of 6 segments were measured in 
the apical 4-chamber view (including the basal, mid and 
apical segments of the septal and lateral walls). The E/
GLSRdias ratio was calculated as the pulsed Doppler 
detected E velocity divided by the  GLSRdias. The ratio 
between apical and basal  LSsys  (LSsysapi/bas) of the sep-
tum was calculated as septal apical  LSsys divided by sep-
tal basal  LSsys.
Statistical analysis
Continuous variables were expressed as mean ± standard 
deviation (SD) or median (quartiles). Categorical vari-
ables were presented as percentages. Non-normally dis-
tributed variables, including N-terminal prohormone brain 
natriuretic peptide (NT-proBNP), E/GLSRdias ratio, and 
 LSsysapi/bas, were normalized prior to analysis. Differences 
on continuous data between groups were compared using 
Student’s t test. Categorical data were compared using Chi 
square test.
Survival curves were plotted by the Kaplan–Meier 
method, and compared by log-rank tests. Cox proportional 
hazards regression was used in multivariable analyses, and 
hazard ratios (HR) with 95% confidence intervals (CI) were 
reported. Outcome was adjusted for age, gender, and body 
mass index. The performance of different prediction mod-
els was judged on the basis of the c-statistic (area under 
the receiver operating characteristic curves). Statistical 
significance was defined as p < 0.05. Statistical analysis 
was performed using IBM SPSS, version 23 for Windows 
(IBM Corp., New York, USA).
Results
Clinical parameters
Fifty-eight AL-CA patients were included (mean age 
64 ± 10 years, 53% male). Their clinical data are listed in 
Table 1. The median duration of follow-up was 365 (quar-
tiles: 121, 365) days. During follow-up, 19 CA patients 
(33%) died. Percent of NYHA functional class III–IV was 
significantly higher in non-survivors than survivors (84% 
vs 36%, p = 0.001). Serum estimated glomerular filtration 
rate (eGFR) was similar between both groups. Serum NT-
proBNP levels were markedly elevated in the whole cohort 
(median 4543 pg/ml) and tended to be higher in non-sur-
vivors compared with survivors (8062 vs. 2595  pg/ml, 
p = 0.181).
Echocardiographic parameters
Conventional echocardiographic data were listed in 
Table  2. LV-FS and LV-EF remained normal or slightly 
reduced, but were significantly lower in non-survivors than 
survivors. Septal MAPSE was significantly reduced in 
the whole cohort as compared to normal value (≥10 mm) 
[14], and was significantly lower in non-survivors than sur-
vivors (p = 0.005). The prevalence of advanced diastolic 
Table 1  Clinical characteristics
BMI body mass index, NYHA New York Heart Association, eGFR estimated glomerular filtration rate, NT-
proBNP N-terminal of the prohormone brain natriuretic peptide
Total Survivors Non-survivors P value
N = 58 N = 39 N = 19
Age (years) 64 ± 10 65 ± 9 64 ± 11 0.618
Male (n, %) 31, 53% 23, 59% 8, 42% 0.227
BMI (kg/m²) 25 ± 4 24 ± 4 26 ± 5 0.123
Systolic blood pressure (mmHg) 116 ± 20 118 ± 18 112 ± 24 0.352
Diastolic blood pressure (mmHg) 73 ± 13 74 ± 12 70 ± 13 0.305
Heart rate (beats/min) 79 ± 12 77 ± 11 84 ± 13 0.070
NYHA functional class (n, %) 0.019
 I 2, 3% 1, 3% 1, 5%
 II 26, 45% 24, 61% 2, 11%
 III 24, 42% 12, 31% 12, 63%
 IV 6, 10% 2, 5% 4, 21%
NYHA class III–IV (n, %) 30, 52% 14, 36% 16, 84% 0.001
eGFR (ml/min/1.73 m²) 62 ± 30 64 ± 32 59 ± 26 0.526
Albumin (g/dl) 3.6 ± 0.8 3.6 ± 0.8 3.8 ± 0.6 0.169
NT-proBNP (pg/ml) 4543 (1615–13,505) 2595 (955–8765) 8062 (3533–16,451) 0.181
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dysfunction (i.e., pseudonormal or restrictive diastolic fill-
ing pattern) was also significantly higher in non-survivors 
than in survivors (87% vs. 54%, p = 0.031).
Tissue Doppler derived Tei index
TD derived-Tei index was 0.70 ± 0.25 in the whole 
cohort, which is markedly higher than normal reference 
value (<0.40) [10]. Tei index was significantly higher in 
non-survivors than in survivors (0.89 ± 0.29 vs. 0.61 ± 0.16, 
p = 0.001).
STI derived systolic and diastolic deformation 
parameters
As shown in Table  2,  GLSRsys and  GLSsys as well as 
 GLSRdias were significantly lower in non-survivors than 
in survivors (all p < 0.05). The E/GLSRdias ratio was 
Table 2  Echocardiographic 
characteristics
LV-EDD left ventricular end-diastolic diameter, IVSd end-diastolic interventricular septal wall thickness, 
LV-PWd end-diastolic left ventricular posterior wall thickness, LV-FS fractional shortening, LV-EF ejec-
tion fraction, SV stroke volume, MAPSE mitral annular plane systolic excursion, LA left atrial, E peak early 
diastolic mitral inflow velocity, E/A peak early to late diastolic mitral inflow velocity ratio, DT deceleration 
time of E wave, E/E′ peak early diastolic mitral inflow velocity to tissue Doppler mitral annular velocity 
ratio, MCO mitral valve closure-to-opening time, ET ejection time, Tei index (MCO-ET)/ET, IVCT iso-
volumetric contract time, IVRT isovolumetric relaxation time, GLSsys global longitudinal systolic strain, 
GLSRsys global longitudinal systolic strain rate, LSsysapi/bas The ratio between apical and basal LSsys of the 
septum, GLSRdias global early diastolic strain rate, E/GLSRdias peak early diastolic mitral inflow velocity to 
global early diastolic strain rate ratio
Total Survivors Non-survivors P value
N = 58 N = 39 N = 19
Standard measurements
 LV-EDD (mm) 45 ± 7 45 ± 7 45 ± 8 0.789
 IVSd (mm) 14.7 ± 3.1 14.1 ± 3.1 15.6 ± 2.9 0.082
 LV-PWd (mm) 14.3 ± 3.2 13.6 ± 3.2 15.1 ± 2.5 0.083
 LV-FS (%) 27 ± 9 30 ± 7 22 ± 8 <0.001
 LV-EF (%) 54 ± 12 58 ± 10 47 ± 13 0.001
 SV (ml) 41 ± 16 42 ± 16 40 ± 17 0.569
 Septal MAPSE (mm) 5.9 ± 2.6 6.6 ± 2.5 4.6 ± 2.2 0.005
 LA (mm) 43 ± 7 43 ± 8 44 ± 6 0.487
 E (cm/s) 0.89 ± 0.23 0.88 ± 0.25 0.92 ± 0.21 0.479
 E/A ratio 1.68 ± 0.91 1.56 ± 0.98 1.84 ± 0.73 0.334
 DT (ms) 161 ± 57 171 ± 58 136 ± 42 0.031
 E/E′ ratio 23.2 ± 10.3 21.7 ± 10.5 27.6 ± 9.6 0.074
Diastolic filling pattern (n, %) 0.170
 Normal 1, 2% 1, 3% 0, 0%
 Abnormal relaxation 16, 28% 14, 36% 2, 10%
 Pseudonormal 16, 28% 10, 26% 6, 32%
 Restrictive 15, 26% 8, 20% 7, 37%
 Atrial fibrillation 10, 17% 6, 15% 4, 21%
Tissue Doppler derived-Tei index
 MCO (ms) 414 ± 59 412 ± 49 418 ± 76 0.712
 ET (ms) 246 ± 35 257 ± 29 223 ± 34 <0.001
 Tei index 0.70 ± 0.25 0.61 ± 0.16 0.89 ± 0.29 0.001
 IVCT (ms) 79 ± 33 70 ± 20 96 ± 44 0.026
 IVRT (ms) 92 ± 27 88 ± 24 98 ± 31 0.185
Longitudinal systolic and diastolic deformation
 GLSsys (%) −10.7 ± 4.3 −12.1 ± 3.6 −8.3 ± 4.6 0.001
 GLSRsys  (S− 1) −0.72 ± 0.29 −0.80 ± 0.26 −0.60 ± 0.32 0.013
 Septal  LSsysapi/bas 3.09 (2.10–4.64) 2.64 (1.99–4.03) 3.36 (2.90–5.68) 0.062
 GLSRdias  (S− 1) 0.79 ± 0.35 0.87 ± 0.30 0.67 ± 0.40 0.039
 E/GLSRdias 1.21 (0.84–1.59) 1.00 (0.76–1.39) 1.65 (0.96–2.44) 0.004
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significantly higher in non-survivors than in survivors 
(p < 0.05).
Survival analysis
Survival analysis (Table 3) showed that NYHA class was 
an independent clinical prognostic marker in this cohort. 
Among conventional echocardiographic and deformation 
parameters, after adjustment for age, gender and body mass 
index, each of the following markers predicted an increased 
1-year mortality risk: LV-FS, LV-EF, septal MAPSE, DT, 
E/E′, ET, IVCT, Tei index,  GLSsys and  GLSRsys, as well as 
E/GLSRsys ratio. The optimal cut-off value for Tei index 
was 0.9 with a specificity of 100% for predicting 1-year 
mortality. Increased Tei index (≥0.9 vs. <0.9, log rank 
p < 0.001), increased E/GLSRdias ratio (≥2.0 vs. <2.0, 
p < 0.001), or reduced  GLSsys (≤13% vs. >13%, p = 0.019) 
in patients with AL-CA was associated with significantly 
increased risk of all-cause death within 1 year (Fig. 2a–c). 
The multivariable regression analysis including NYHA 
class, LV-EF, septal MAPSE, E/E′ and Tei index showed 
that NYHA class III–IV (HR 6.79, p = 0.025) and Tei index 
≥0.9 (HR 12.33, p = 0.001) remained independent predic-
tors in this model. Furthermore, the model including defor-
mation predictors  (GLSsys and E/GLSRdias) and Tei index 
demonstrated that Tei index ≥0.9 was the best independent 
predictor of all-cause mortality risk (HR 7.01, p < 0.001).
Prediction model performance statistics (Table  4) 
revealed that Tei index alone already yielded very good 
predictive utility (c-statistic: 0.85). Adding deformation 
predictors  (GLSsys or E/GLSRdias) only slightly increased 
this value (c-statistic: 0.87). Other approaches yielded no 
further favorable utility, e.g.,  GLSsys (c-statistic 0.77), E/
GLSRdias (c-statistic 0.72) or  GLSsys + E/GLSRdias (c-sta-
tistic 0.77).
As shown in Fig. 3, 9 out of 9 (100%) patients with Tei 
index ≥0.9 and  GLSsys absolute value ≤13% died during 
1-year follow up (specificity 100%, positive predictive 
value 100%; sensitivity 47%). In contrast, only 1 out of 16 
(6%) patients with Tei index <0.9 and  GLSsys >13% died 
within 1 year.
As shown in Fig. 4, in patients with NYHA class I–II, 
a significantly increased Tei index (≥0.9) was presented 
in none (0/20) of survivors, whereas in 25% (2/8) of 
Table 3  Cox proportional 
hazard regression for 1-year all-
cause mortality in patients with 
light-chain cardiac amyloidosis
Abbreviations as in Tables 1 and 2
Hazard ratio (95% confidence interval), 
adjusted for age, gender and BMI
P value
NYHA class III–IV vs. I–II 6.55 (1.89–22.75) 0.003
LV-FS (%) 0.91 (0.86–0.97) 0.002
LV-EF (%) 0.95 (0.91–0.99) 0.009
Septal MAPSE (mm) 0.73 (0.58–0.91) 0.006
DT (ms) 0.98 (0.97–0.99) 0.002
E/E′ 1.05 (1.00–1.10) 0.038
ET (ms) 0.98 (0.96–0.99) 0.001
IVCT (ms) 1.01 (1.01–1.02) 0.002
Tei index 47.04 (7.79–284.10) <0.001
Tei index ≥0.9 vs. <0.9 8.48 (3.27–21.99) <0.001
GLSsys (%) 1.18 (1.06–1.33) 0.004
GLSRsys  (S− 1) 8.33 (1.55–44.78) 0.014
Septal  LSsysapi/bas 1.36 (0.83–2.23) 0.223
GLSRdias  (S− 1) 0.24 (0.06–1.01) 0.051
E/GLSRdias 1.92 (1.19–3.08) 0.007
Model including Tei index, NYHA class and other conventional echocardiographic variables
 NYHA class III–IV vs. I–II 6.79 (1.27–36.39) 0.025
 LV-EF (%) 1.04 (0.96–1.13) 0.309
 Septal MAPSE (mm) 0.85 (0.68–1.06) 0.153
 E/E′ 0.99 (0.92–1.06) 0.788
 Tei index ≥0.9 vs. <0.9 12.33 (2.92–52.04) 0.001
Model including Tei index and deformation variables
 GLSsys ≤13% vs. >13% 3.88 (0.84–17.93) 0.082
 E/GLSRdias ≥2.0 vs. <2.0 1.44 (0.48–4.35) 0.517
 Tei index ≥0.9 vs. <0.9 7.01 (2.43–20.21) <0.001
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non-survivors (p = 0.074). Conversely, in patients with 
NYHA class III–IV, a normal Tei index (<0.5) was found 
in 18.2% (2/11) of survivors and in 26.3% (5/19) of non-
survivors (p > 0.05).
Discussion
The major findings of the present study are as follows: (1) 
increased Tei index (≥ 0.9) served as a valuable independ-
ent predictor of all-cause mortality during 1-year follow 
up in AL-CA patients, which was superior to LV-EF and 
other conventionally derived diastolic indices, and similar 
to both global longitudinal systolic strain and E to global 
early diastolic strain rate ratio; and (2) combining Tei index 
(threshold ≥0.9) and  GLSsys (≤13%) yielded excellent 
prognostic utility allowing improved mortality risk stratifi-
cation in AL-CA patients.
Tei index as the best echocardiographic predictor 
for outcome assessment in AL-CA patients
The Tei index is an easy-to-obtain parameter, it not only 
reflects combined systolic and diastolic myocardial func-
tion, but is also independent of heart rate and blood pres-
sure [10]. Although conventional measurements of systolic 
function such as LV-EF, LV-FS, or MAPSE proved to be 
feasible for prediction of outcome in this cohort, their prog-
nostic power was weaker than Tei index. This might be due 
to the fact that the Tei index has the unique merit that it 
does not depend on ventricular geometry and image quality 
[15].
The potential of the Tei index as a clinically meaning-
ful diagnostic and prognostic marker has been reported in 
various reports investigating symptomatic heart failure, 
acute myocardial infarction, dilated cardiomyopathy, and 
primary pulmonary hypertension [16–19]. Tei et  al. also 
demonstrated the prognostic significance of the Tei index 
in patients with CA comprising patients with primary, 
familial and senile amyloidosis [9]. Our results extend 
their findings, documenting that amongst a large variety of 
conventional echocardiographic markers the Tei index per-
formed best in independently predicting 1-year mortality 
in AL-CA patients, superior to evaluation of NYHA class, 
Fig. 2  Kaplan–Meier estimation of Tei index,  GLSsys, and E/GLSR-
dias for predicting all-cause mortality in patients with light-chain car-
diac amyloidosis (AL-CA). Note that increased Tei index (a ≥0.9, 
P < 0.001), reduced  GLSsys (b ≤13%, p = 0.019), or increased E/
GLSRdias ratio (c ≥2.0, P < 0.001) was associated with significantly 
increased risk of all-cause death within 1 year in patients with 
AL-CA. GLSsys global longitudinal systolic strain, E/GLSRdias peak 
early diastolic mitral inflow velocity to global early diastolic strain 
rate ratio
▸
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LV-EF (=global systolic function), septal MAPSE (=lon-
gitudinal global systolic function), DT or E/E′ (=diastolic 
function).
As stated above, the Tei index is computed by the for-
mula (IVCT + IVRT)/ET. Tei et al. reported that the IVRT 
and IVCT components were significantly prolonged and 
the ET was significantly shortened in CA patients as com-
pared with normal controls [9]. Consistently, the present 
study also demonstrated a remarkably shorter ET and 
longer IVCT and IVRT in non-survivors than in survivors. 
A possible reason for the observed ET shortening might be 
associated with lower end-diastolic volumes. In AL-CA, 
the end-diastolic volume is limited due to amyloid deposi-
tion, which consequently results in a stiff ventricle. Migrino 
et al. showed that ET was the most important predictor of 
adverse outcome in AL amyloidosis [20]. In our cohort, ET 
was confirmed as an independent predictor of 1-year all-
cause mortality risk, and ET ≤230 ms showed a similarly 
good prediction performance, with a sensitivity of 68% and 
a specificity of 85%. Prolongation of IVCT and IVRT are 
also evidenced, especially in non-survivors in the present 
study, which indicates reduced myocardial contractility 
and abnormal myocardial relaxation in these patients [21]. 
Accordingly, the prevalence of advanced diastolic dysfunc-
tion was remarkably higher in non-survivors (87%) than 
survivors (54%, p < 0.05).
Prognostic utility of Tei index and STI-derived 
deformation imaging in AL-CA patients
As mentioned before, the longitudinal function assessed by 
TDI derived strain was reduced in patients with AL amy-
loidosis, which also had an important prognostic relevance 
Table 4  Model performance 
statistics for Tei index and 
deformation predictors related 
1-year all-cause mortality in 
patients with light-chain cardiac 
amyloidosis
Abbreviations as in Table 2
Overall performance Discrimination (ROC, c-statistic)
Nagelkerke R² c-statistic (95% CI) P value
Tei index 0.40 0.85 (0.74–0.95) <0.001
GLSsys (%) 0.29 0.77 (0.64–0.90) 0.001
E/LSRdias 0.22 0.72 (0.58–0.87) 0.007
Tei index + GLSsys (%) 0.45 0.87 (0.76–0.97) <0.001
Tei index + E/GLSRdias 0.45 0.87 (0.77–0.97) <0.001
GLSsys (%) + E/GLSRdias 0.32 0.77 (0.63–0.90) 0.001
Fig. 3  Comparison of prognostic performance of Tei index ≥0.9 and 
 GLSsys ≤13% in patients with light-chain cardiac amyloidosis. Scat-
ter plots depicting the correct and wrong attribution of having died 
after 1 year of follow-up using certain thresholds derived from study 
data. Excellent prognostic performance for predicting 1-year all-cause 
mortality is observed using Tei index ≥0.9 plus  GLSsys ≤13% with a 
specificity of 100% and a sensitivity of 47%. GLSsys global longitudi-
nal systolic strain, Sp specificity, Se sensitivity
Fig. 4  Comparison of prognostic performance of Tei index between 
light-chain cardiac amyloidosis patients with NYHA class I–II and 
III–IV. Note that in patients with NYHA class I–II, a significantly 
increased Tei index (≥0.9) was present in none (0/20) of survivors, 
but in 25% (2/8) of non-survivors (p = 0.074). Conversely, in patients 
with NYHA class III–IV, a normal Tei index (<0.5) was found in 
18.2% (2/11) of survivors and in 26.3% (5/19) of non-survivors 
(p > 0.05). NYHA class New York Heart Association functional class
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[22]. In the present study, apart from conventional echocar-
diographic indices, we focused on the comparison of prog-
nosis performance between the Tei index and STI-derived 
deformation predictors. Deformation imaging has been 
well recognized over the last decade as a novel technology, 
which provides more accurate and sensitive assessment of 
global and segmental myocardial function in various car-
diac conditions. The diagnostic and prognostic values of 
STI-derived strain rate measurements in CA patients have 
been demonstrated by our group and others [6, 22, 23]. 
Consistent with our previous study [7],  GLSRdias and E/
GLSdias independently predicted outcome in this cohort. 
However, the prognostic power of all these deformation 
markers was somehow weaker than that of the Tei index 
(c-statistics:  GLSsys 0.77, E/GLSRdias 0.72, Tei index 0.85). 
Since good imaging quality is the essential prerequisite 
of the measurements of  GLSRdias and E/GLSdias, while 
Tei index could be reliably and easily obtained even in 
patients with unsatisfactory imaging condition, the present 
study underscores the priority of using Tei index instead 
of  GLSRdias and E/GLSdias for the outcome assessment of 
AL-CA patients.
We further investigated the incremental predictive power 
of the Tei index and deformation imaging parameters. In 
particular, thresholds of Tei index ≥0.9 and  GLSsys ≤13% 
were analyzed (Fig. 3). We found that this combination per-
formed well in predicting 1-year all-cause mortality with 
perfect specificity (100%) and positive predictive value 
(100%), negative predictive value of 80%, whereas sensitiv-
ity was 47%. Of note, the prediction of survival was also 
very good when this combination was used, with a specific-
ity of 95% (but with a low sensitivity of 38%). Our results 
thus suggest that the combination of Tei index and  GLSsys 
can serve as a valuable tool to improve risk stratification in 
AL-CA patients. This might have important clinical impli-
cations regarding therapy regime, such as differentiating 
patients eligible for standard or high-dose chemotherapy, 
or to identify patients in need of stem cell replacement or 
heart transplantation.
Since NYHA functional class was a dominant predic-
tor of mortality risk in this cohort, we further analyzed 
the prognostic role of Tei index in subgroups of NYHA 
class I–II vs class III–IV, respectively. The results showed 
that in the subgroup of NYHA class I–II, the Tei index 
was significantly higher in non-survivors than in survi-
vors (0.81 ± 0.26 vs. 0.59 ± 0.13, p = 0.007). Likewise, in 
patients with NYHA class III–IV, the Tei index also tended 
to be higher in non-survivors than survivors, but this 
trend did not reach statistical significance (0.80 ± 0.31 vs. 
0.64 ± 0.22, p = 0.152). These results suggest that the Tei 
index might be useful to predict prognosis of CA patients 
without overt clinical heart failure (NYHA class I–II), 
whereas the predictive value of the Tei index was somehow 
weaker in CA patients with more advanced heart failure 
symptoms (NYHA class III–IV). These findings need to be 
confirmed in future prospective studies with larger sample 
sizes.
Technical considerations
In the present study, STI derived global strain was obtained 
from 4-chamber apical views only. In a pilot study, we 
compared the difference of global longitudinal strain value 
derived from all three apical views and a single 4-chamber 
apical view in 20 AL-CA patients, and observed similar 
strain values derived from all three apical views  (GLSsys 
−10.9 ± 3.7%) and a single 4-chamber apical view  (GLSsys 
−10.7 ± 4.4%, p = 0.674). Since imaging quality of the 
apical 4-chamber view is in usually superior compared to 
apical 2-chamber and long-axis views, the evaluation was 
thus performed based on apical 4-chamber view in the 
present study to shorten the evaluation time and pave the 
way for broader use of this technique in real world clinical 
situations.
Study limitations
The current cohort included only a relatively small sample 
of a single subtype of cardiac amyloidosis, AL amyloidosis. 
The prognostic utility of the Tei index in combination with 
longitudinal strain should be validated in other subtypes 
such as hereditary or wild-type transthyretin amyloidosis. 
This might have particularly clinical relevant implications, 
as a specific medical therapy of transthyretin amyloidosis is 
expected to be clinically available very soon. Future clini-
cal studies with ideally larger sample sizes are warranted 
to externally validate the proposed risk stratification strat-
egy, compare the findings between the various entities of 
cardiac amyloidosis, and evaluate potential implications on 
therapy planning.
Conclusions
Both Tei index and STI-derived deformation parameters 
can be used to predict mortality risk in AL-CA patients 
with superior prognostic value compared to conventional 
echocardiographic parameters. However, the prognostic 
power of deformation markers is somehow weaker than 
that of the Tei index. The Tei index can easily be obtained, 
even under difficult imaging conditons. The combination 
of Tei index and selected deformation parameters, such as 
Tei index plus  GLSsys, provides excellent predictive util-
ity for 1-year outcome and might therefore prove clinically 
valuable for risk stratification in this clinically demanding 
patient group.
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